Producers Online
Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish efficacy of GTX-102 Phase 3 program on track to begin…
NEW YORK, Nov. 10, 2024 (GLOBE NEWSWIRE) -- NEW YORK, November 10, 2024 /GlobeNewswire/-- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders…
MIAMI, FL, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Clover Leaf Capital Corp. (OTC: CLOE) (the “Company” or “Clover Leaf”), announced today that Clover Leaf and Kustom Entertainment, Inc. (“Kustom Entertainment”)…
DEARBORN, Mich. and WINTER PARK, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- DFCU Financial, one of Michigan's largest and most trusted credit unions, is pleased to announce its intent to…
Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with similar frequency, depth, duration, and kinetics Initial biomarker data shows…
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort of FT825 / ONO-8250 as Monotherapy Shows Favorable Safety Profile…
PRESS RELEASEIvry-sur-Seine, France — November 8, 2024, 19h15 CEST THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IS NOT PERMITTED IN…
COMUNICATO STAMPAIvry-sur-Seine, Francia — 8 novembre 2024, 19h15 CEST È VIETATA LA DIVULGAZIONE, LA PUBBLICAZIONE O LA DISTRIBUZIONE DEL PRESENTE COMUNICATO, IN TUTTO O IN PARTE, IN O VERSO GLI…
BURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of ciforadenant, the Company’s adenosine A2A…
LONDON, Province de l’Ontario, 09 nov. 2024 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc., ci-après « Aduro » ou la « Société » (Nasdaq : ADUR) (CSE : ACT) (FSE…